MARKETING AUTHORISATION

MARKETING AUTHORISATION
Arthur Cummings
Published: Monday, April 13, 2015

Santen Pharmaceutical has announced that the European Medicines Agency (EMA) has accepted the company’s Marketing Authorisation Application (MAA) filing for the use of intravitreal sirolimus, an investigational mTOR inhibitor, for the treatment of noninfectious uveitis (NIU) of the posterior segment.
“Given the risks associated with currently available therapeutic options for NIU of the posterior segment, a chronic inflammatory condition in many cases, there is a significant need for novel treatments that could be used,” says Dr Naveed Shams, Chief Scientific Officer and Head, Global R&D, Santen Ltd.
www.santeninc.com

Latest Articles
Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Nutrition and the Eye: A Recipe for Success

A look at the evidence for tasty ways of lowering risks and improving ocular health.

Read more...

New Award to Encourage Research into Sustainable Practices

Read more...

Sharing a Vision for the Future

ESCRS leaders update Trieste conference on ESCRS initiatives.

Read more...

Extending Depth of Satisfaction

The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.

Read more...

Conventional Versus Laser-Assisted Cataract Surgery

Evidence favours conventional technique in most cases.

Read more...

AI Scribing and Telephone Management

Automating note-taking and call centres could boost practice efficiency.

Read more...